17 December 2013 – EU authorisation
Further progress has been made towards the successful commercialisation of the group’s Parsortix diagnostic system with the CE Mark authorisation of the blood cell separation system for use as an in vitro diagnostic device in the EU. This will allow the group with regulatory authorisation for clinical sales in Europe and provides a platform to explore relationships with major pharmaceutical and medical companies. The group is preparing a similar submission to the FDA in the US which should be submitted by the end of Q1 2014. The shares remain a BUY.